Cognoa’s AI-driven device is the first FDA-authorized diagnosis aid designed to help primary care physicians diagnose autism in young children with the goal of shortening time-to-diagnosis and enabling initiation of earlier interventions (Palo Alto, Calif. – June 2nd, 2021) – Cognoa, a pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with behavioral health conditions, today announced…
By: Lani Hessen, Director of Advocacy, Cognoa, and Pediatric Occupational Therapist (OTR/L) Autism impacts an estimated 1 in 54 children in the U.S. today. Autism is a spectrum, representing a tremendous range of skills and challenges spanning learning and communication, socialization and developmental behaviors. Autism impacts children and families of all backgrounds, regardless of race, ethnicity, location, or wealth. As…
By David Happel This article was originally published in Autism Parenting Magazine, Issue 118. Nearly 80 years after psychiatrist Leo Kanner became the first physician to use the term “autism”, children and families with autism still face critical gaps and unnecessary delays on their way to a diagnosis. Rather than diagnosing children themselves, pediatricians typically refer children with suspected developmental delays to specialists—setting…
Mosbrooker will be leading the operational and commercial efforts of Cognoa’s digital behavioral health products (Palo Alto, Calif. – January 14, 2021) – Cognoa, the leading pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with autism and other behavioral health conditions, today announced the appointment of Eric B. Mosbrooker as Chief Operations Officer. Mosbrooker will be…
Written By Jason Hartman As a part of our series about business leaders who are shaking things up in their industry, I had the pleasure of interviewing David Happel. David Happel is the President and CEO of Cognoa, the leading digital diagnostics and therapeutics company developing FDA cleared pediatric behavioral health solutions. Prior to joining Cognoa, Happel served as President,…
by Katie Cloyd – December 18, 2020 So, you think your young child might be on the autism spectrum. Maybe they’re not talking or communicating as expected, or they don’t seem to understand when you talk to them. Perhaps they seem exceptionally frustrated and their tantrum behaviors don’t seem developmentally typical to you. Like many other parents, I have been there. My son was…
Graison Dangor Contributor Healthcare I cover the intersection of mental health, the economy, and policy. A tool that helps pediatricians diagnose autism with artificial intelligence and smartphone video passed a key FDA test and could hit the market as soon as next summer, according to device-maker Cognoa, which recently announced its plans to submit the tool for final approval. In…
By Meg Bryant Children with autism spectrum disorder (ASD) can face a lifetime of frustration because of challenges with communication, social behaviors and flexibility of thought. Early intervention can improve outcomes, but nailing a diagnosis of ASD often takes years. Cognoa Inc. wants to change that with its digital ASD Diagnostic and is on track to apply for U.S. FDA clearance before the…
by Conor Hale Cognoa aims to equip primary care pediatricians with an artificial-intelligence-powered digital app that can spot the signs of autism, allowing them to rule out or diagnose spectrum disorders within the doctor’s office or remotely. This could represent a broad shift in the standard of care, as most children are referred to specialists for diagnosis and later treatment—a process…
The startup Cognoa has submitted its app-based tool for FDA clearance By Megan Scudellari This week, a California-based company announced it will seek FDA clearance for a first-of-its-kind autism spectrum disorder (ASD) diagnostic tool. Cognoa’s technology uses artificial intelligence to make an ASD diagnosis within weeks of signs of concern—far faster than the current standard of care. If cleared by the FDA, it would be…
